160 related articles for article (PubMed ID: 27184224)
1. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.
Kim JW; Auffinger B; Spencer DA; Miska J; Chang AL; Kane JR; Young JS; Kanojia D; Qiao J; Mann JF; Zhang L; Wu M; Ahmed AU; Aboody KS; Strong TV; Hébert CD; Lesniak MS
J Transl Med; 2016 May; 14(1):134. PubMed ID: 27184224
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats.
Sonabend AM; Ulasov IV; Han Y; Rolle CE; Nandi S; Cao D; Tyler MA; Lesniak MS
Cancer Gene Ther; 2009 Apr; 16(4):362-72. PubMed ID: 19011597
[TBL] [Abstract][Full Text] [Related]
4. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
5. A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect.
Paupoo AA; Zhu ZB; Wang M; Rein DT; Starzinski-Powitz A; Curiel DT
Hum Reprod; 2010 Aug; 25(8):2068-83. PubMed ID: 20573677
[TBL] [Abstract][Full Text] [Related]
6. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
[TBL] [Abstract][Full Text] [Related]
7. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
[TBL] [Abstract][Full Text] [Related]
8. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
Kim KH; Ryan MJ; Estep JE; Miniard BM; Rudge TL; Peggins JO; Broadt TL; Wang M; Preuss MA; Siegal GP; Hemminki A; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
Hum Gene Ther; 2011 Jul; 22(7):821-8. PubMed ID: 21171861
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.
Kim CK; Ahmed AU; Auffinger B; Ulasov IV; Tobias AL; Moon KS; Lesniak MS
Mol Ther; 2013 Nov; 21(11):2063-73. PubMed ID: 23883863
[TBL] [Abstract][Full Text] [Related]
10. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
[TBL] [Abstract][Full Text] [Related]
11. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
12. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
[TBL] [Abstract][Full Text] [Related]
13. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
[TBL] [Abstract][Full Text] [Related]
14. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
[TBL] [Abstract][Full Text] [Related]
15. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.
Morshed RA; Gutova M; Juliano J; Barish ME; Hawkins-Daarud A; Oganesyan D; Vazgen K; Yang T; Annala A; Ahmed AU; Aboody KS; Swanson KR; Moats RA; Lesniak MS
Cancer Gene Ther; 2015 Jan; 22(1):55-61. PubMed ID: 25525033
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
[TBL] [Abstract][Full Text] [Related]
17. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
[TBL] [Abstract][Full Text] [Related]
18. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
19. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
Dhar D; Toth K; Wold WS
Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
[TBL] [Abstract][Full Text] [Related]
20. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
Ahmed AU; Thaci B; Tobias AL; Auffinger B; Zhang L; Cheng Y; Kim CK; Yunis C; Han Y; Alexiades NG; Fan X; Aboody KS; Lesniak MS
J Natl Cancer Inst; 2013 Jul; 105(13):968-77. PubMed ID: 23821758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
